Tempus AI (NASDAQ:TEM) EVP Erik Phelps Sells 1,302 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 1,302 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total transaction of $87,780.84. Following the sale, the executive vice president owned 89,280 shares of the company’s stock, valued at approximately $6,019,257.60. This represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Erik Phelps also recently made the following trade(s):

• On Tuesday, November 18th, Erik Phelps sold 3,533 shares of Tempus AI stock. The shares were sold at an average price of $65.54, for a total transaction of $231,552.82.

Tempus AI Stock Down 3.7%

Shares of TEM stock traded down $2.40 during midday trading on Thursday, reaching $62.21. 5,950,298 shares of the stock were exchanged, compared to its average volume of 10,642,942. The firm has a market cap of $11.07 billion, a PE ratio of -52.28 and a beta of 4.99. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The company’s 50 day moving average is $79.21 and its two-hundred day moving average is $73.72. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same period last year, the company posted ($0.46) EPS. Tempus AI’s revenue was up 84.7% on a year-over-year basis. On average, equities research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current year.

Analyst Ratings Changes

TEM has been the subject of a number of research analyst reports. BTIG Research lifted their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Morgan Stanley boosted their price objective on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Needham & Company LLC boosted their target price on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, HC Wainwright dropped their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $85.36.

Institutional Trading of Tempus AI

A number of large investors have recently modified their holdings of the company. Cranbrook Wealth Management LLC bought a new position in Tempus AI during the 3rd quarter worth about $25,000. Concord Wealth Partners increased its position in Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after buying an additional 308 shares in the last quarter. JPL Wealth Management LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the third quarter worth $28,000. Finally, Allworth Financial LP grew its stake in Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.